Tinzaparin in pediatric intensive care patients

Dosing and therapeutic drug monitoring of tinzaparin on the pediatric intensive care unit

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26406

Enrollment

Registered

2016-10-31

Start date

2016-09-12

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

No specific interventions. Observational studie.

Eligibility

Inclusion criteria

Inclusion criteria: Patients on the pediatric intensive care unit with tinzaparin as therapeutic anticoagulation

Exclusion criteria

Exclusion criteria: - Patients with tinzaparin as profylactic anticoagulation - Patients with an coagulation disorder

Design outcomes

Primary

Measure	Time frame
- Anti-Xa levels - Time till adequate anti-Xa levels - Doses that lead to adequate anti-Xa levels	—

Secondary

Measure	Time frame
- Influence of renal function - Influence of hepatic function - Comedication - Presence of edema - Disease severity (PRISM score)	—

Contacts

Public ContactP.P. Roeleveld

LUMC

P.P.Roeleveld@lumc.nl

Outcome results